EU/3/16/1760

Table of contents

About

On 14 October 2016, orphan designation (EU/3/16/1760) was granted by the European Commission to Wainwright Associates Ltd, United Kingdom, for radio-iodinated (131I) anti-CD45 murine monoclonal antibody (also known as Iomab-B) for treatment in haematopoietic stem cell transplantation.

In November 2016, Wainwright Associates Ltd changed name to PharmaLex UK Services Limited.

The sponsorship was transferred to YES Pharmaceuticals Development Services GmbH, Germany, in April 2019.

Key facts

Active substance
Radio-iodinated (131I) anti-CD45 murine monoclonal antibody
Disease / condition
Treatment in haematopoietic stem cell transplantation
Date of first decision
14/10/2016
Outcome
Positive
EU designation number
EU/3/16/1760

Sponsor's contact details

Yes Pharmaceutical Development Services GmbH
Bahnstraβe 42-46
61381 Friedrichsdorf
Germany
Tel. +4961727646465
E-mail: martyn.critchley@pharmalex.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating